CALC Insider Eric Roberts Buys Shares

Eric Roberts, the Chief Business Officer at CALC, purchased 186,729 shares of the company at an average price of $0.80 per share. This transaction, valued at approximately $149,383, took place on June 25, 2026, and was not made under a pre-planned trading program.

Other Institutional Activity in CALC

Jane Street Group significantly increased its holdings in CALC by 159,312 shares, ending with 178,515 shares valued at about $96,398. Vanguard Capital Management opened a new position, acquiring 169,110 shares worth approximately $91,319. Renaissance Technologies added 39,775 shares, bringing its total to 128,075 shares valued at $69,161, marking a 45% increase. 180 Wealth Advisors also boosted its position by 94,650 shares, now holding 126,500 shares valued at $68,310, representing a 297.2% increase. Geode Capital Management added 23,595 shares to reach a total of 123,382 shares, valued at $66,652, reflecting a 23.6% increase.

CalciMedica, Inc. Stock Down 64.9%

Shares of CALC traded near $0.82 on Monday. The stock has seen various institutional activities, suggesting interest from different market players. While specific financial metrics like market cap and P/E ratio are not provided, the recent insider and institutional transactions could indicate confidence in the company's future prospects.

Insider Buying and Selling at CalciMedica, Inc.

In addition to Eric Roberts, several other insiders made purchases on June 25, 2026. Rachel Leheny, the Chief Executive Officer, bought 186,729 shares at $0.80 each. Chief Medical Officer Sudarshan Hebbar acquired 124,486 shares at the same price. Robert Wilson purchased 1,182,621 shares, and Fred Middleton bought 248,972 shares, all at $0.80 per share. These transactions were not part of a pre-planned trading program.

Analysts Set New Price Targets

On March 5, 2026, Oppenheimer maintained its 'buy' rating for CALC with a price target of $10. HC Wainwright & Co. has repeatedly reiterated its 'buy' rating, setting a target of $16 in previous assessments. Lucid Capital Markets initiated coverage with a 'buy' rating and a $13 target on December 19, 2024.

Bottom Line

Eric Roberts' recent purchase of CALC shares, along with other insider activities, suggests a notable level of confidence among company executives. Institutional investors have also been active, with several funds significantly adjusting their positions. These insights, coupled with analyst ratings, provide a comprehensive view of the current sentiment surrounding CALC. However, it's important to remember that insider transactions and 13F filings are backward-looking and may not fully reflect the current investment landscape.